Erste Group analyst Hans Engel resumed coverage of Regeneron with a Buy rating, removing the stock from Under Review, following the company’s successful phase 3 study in COPD. The company’s shares are "moderately valued in view of the very positive growth prospects," said the firm, which thinks Dupixent has the potential to "strongly expand" sales in the coming years.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
- Immuneering appoints Harold Brakewood as CBO
- Regeneron Pharmaceuticals, Sonoma Biotherapeutics announce collaboration
- Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
- SVB Securities upgrades Regeneron to Outperform, sees positive drivers ahead